|
|
|
| Therapeutic Effect of Letrozole Combined with HCG on Patients with Polycystic Ovary Syndrome |
| DING Xia, PAN Chang-qing |
| Department of Gynecology, Shanghai Jiahua Hospital, Shanghai 201800 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of letrozole combined with HCG in the treatment of patients with polycystic ovary syndrome. 【Methods】A total of 120 PCOS patients admitted to gynecology department of our hospital from January 2015 to August 2018 were selected and divided into observation group and control group according to random number table method, 60 cases in each group. The control group was treated with letrozole, while the observation group was treated with HCG on the basis of the control group. The levels of sex hormones testosterone (T), progesterone (PRGE), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2), vascular endothelial growth factor (VEGF), endostatin (ES) and the incidence of clinical efficacy and adverse reactions were compared between the two groups. 【Results】After treatment, the levels of T, FSH, LH, E2, VEGF and ES in the two groups were significantly decreased, but the levels of each index in the observation group were significantly lower than those in the control group (P<0.05); the ovarian volume in the observation group was significantly smaller than that in the control group, while the follicle diameter and the number of follicles in the observation group were significantly larger than those in the control group, the difference was statistically significant (P<0.05), but the endometrial thickness in the two groups was significantly different (P<0.05). There was no significant difference between the two groups (P>0.05). The ovulation rate and pregnancy rate in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Letrozole combined with HCG in the treatment of PCOS can effectively reduce the levels of sex hormones, vascular endothelial growth factor and ES, improve ovulation and pregnancy rate. It is safe and worthy of clinical application.
|
|
Received: 13 December 2018
|
|
|
|
|
|
[1] Jiao J , Fang Y , Wang T,et al.Epidemiologic investigation of polycystic ovarian syndrome (PCOS) in Han ethnic women of reproductive age in Liaoning Province, China[J].Clin Exp Obstet Gynecol,2014, 41(3):304-309.
[2] 谢芸,吕君,王朝华.多囊卵巢综合征排卵障碍82例促排卵临床分析[J].中国妇产科临床杂志,2018,19(4):295-298.
[3] 任凤岩, 李一宁, 王丹波,等. 血管生成与多囊卵巢综合征发病机制的关系[J].中国全科医学, 2007, 10(13):1121-1123.
[4] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J].Fertil Steril,2004, 81(1):19-25.
[5] 王淑芳. 不同剂量来曲唑联合HCG治疗多囊卵巢综合征促排卵的临床研究[J].实用药物与临床, 2013, 16(1):69-70.
[6] 石丽琼, 陈晓兰. 来曲唑与克罗米芬治疗多囊卵巢综合征促排卵疗效分析[J].中国医学创新, 2012, 9(21):139-140.
[7] 叶玲玲, 吴伟建, 曹文丽. 来曲唑促排卵治疗多囊卵巢综合征疗效观察[J].中国临床药理学杂志, 2009, 25(5):399-401.
[8] Carmina E,Longo A , Lobo RA . Does ovarian blood flow distinguish between ovulatory and anovulatory patients with polycystic ovary syndrome[J].Am J Obstet Gynecol,2003, 189(5):1283-1286.
[9] Paloal PG,Massimiliano M,Cristian M,et al.Vascular endothelial growth factor and basis fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hypersti mulation[J].Gynecol Endocrinol,2006,22(12):465-470. |
|
|
|
2019, Vol. 36 
